Loading...
Anaplastic large-cell lymphoma (ALCL), a CD30-positive disease that may be systemic or localized (most commonly in cutaneous sites), responds well to the anti-CD30 drug-antibody conjugate brentuximab vedotin (BV).
Now, investigators have conducted an industry-sponsored, multicenter, phase II trial to test the efficacy and safety of single-agent BV in 58 patients with relapsed or refractory systemic ALCL following chemotherapy. Responding patients could undergo stem cell transplant (SCT) consolidation.
A total of 38 patients (66%) achieved complete remission. At a median follow-up of 6 years, 16 patients (28%) remained in remission at 5 years, of whom half underwent SCT and half received no further therapy. Peripheral neuropathy, a known side …